GDF15 Circulating Levels Are Associated with Metabolic-Associated Liver Injury and Atherosclerotic Cardiovascular Disease
Authors:
- Josefa GironaJGJosefa Girona
- Montse GuardiolaMGMontse Guardiola
- Emma BarrosoEmma Barroso
- María García-AltaresMGMaría García-Altares
- Daiana IbarretxeDIDaiana Ibarretxe
- Núria PlanaNPNúria Plana
- Josep RibaltaJRJosep Ribalta
- Núria AmigóNANúria Amigó
- Xavier CorreigXCXavier Correig
- Manuel Vázquez-CarreraManuel Vázquez-Carrera
- Lluís MasanaLMLluís Masana
- Ricardo Rodríguez-CalvoRRRicardo Rodríguez-Calvo
Open Access
- 26 February 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (5) , 2039
Abstract
There is growing evidence linking growth differentiation factor 15 (GDF15) to both metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascular (CV) risk. Nevertheless, the potential relationship between circulating levels of GDF15 and key features of MASLD being predisposed to atherosclerotic CV disease is not fully unveiled. The aim of this study was to deepen into the role of circulating GDF15 levels on metabolic-associated liver injury and atherosclerotic CV disease. We determined the serum GDF15 levels in 156 participants of a metabolic patient-based cohort, and cross-sectionally explored its associations with liver injury and an advanced atherosclerotic lipoprotein profile assessed by nuclear magnetic resonance (1H-NMR). Additionally, we prospectively evaluated the association between GDF15 levels at baseline and incident atherosclerotic CV disease after a 10-year follow-up. GDF15 was related to liver injury and inflammatory hallmarks, and it increased the likelihood for liver steatosis independently of confounding factors. Likewise, GDF15 was positively associated with an atherogenic profile, particularly with the number of very-low-density lipoproteins (VLDL) particles and its cholesterol and triglyceride content, and with an indicator of subclinical atherosclerosis (i.e., carotid intima–media thickness (cIMT)). The baseline serum GDF15 levels were higher in the patients with atherosclerotic CV disease (10.6%) after a 10-year follow-up than in the individuals without CV disease. Altogether, this study provides new insights into the role of GDF15 in both MASLD and CV disease.Keywords
Funding Information
- CIBER (Consorcio Centro de Investigación Biomédica en Red) (CB07/08/0028, PID2021-122116OB-I00)
- Ministerio de Ciencia e Innovación (CB07/08/0028, PID2021-122116OB-I00)
This publication has 45 references indexed in Scilit:
- Growth differentiation factor 15: Emerging role in liver diseasesCytokine, 2024
- Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without AtherosclerosisJAMA Cardiology, 2021
- VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing LipoproteinsJACC, 2020
- The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated DiseasesCell Metabolism, 2018
- The Natural History of Nonalcoholic Fatty Liver Disease—An Evolving ViewClinics in Liver Disease, 2018
- Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of VeteransClinical Gastroenterology and Hepatology, 2016
- Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver DiseaseClinical Gastroenterology and Hepatology, 2016
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomesHepatology, 2015
- Lipoprotein Particle Analysis by Nuclear Magnetic Resonance SpectroscopyClinics In Laboratory Medicine, 2006
- Long‐term follow‐up of patients with NAFLD and elevated liver enzymes†‡Hepatology, 2006